Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Regulatory Approval To Open Clinical Study of AT-H201 in Australia

SEATTLE, Nov. 07, 2022 — Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments.

Key developments from Q3 2022 and to date include:

  • Received FDA authorization from FDA to initiate its Phase 2 study of neoadjuvant (Z)-endoxifen in premenopausal women with ER+/HER2- breast cancer.
  • Invested in a privately-held Dynamic Cell Therapies, a company focused on CAR-T therapies as an important step in pursuing its strategy to develop CAR-T therapies or adjacent opportunities within the immuno-oncology space.
  • Completed dosing in both Part B and Part C (of four parts) of Phase 1/2a Clinical Trial of AT-H201 in healthy volunteers, which the Company is now developing for patients with compromised lung function due to the damaging effects of cancer treatment.

“We continue to make progress with our (Z)-endoxifen programs. In particular, our Phase 2 study of neoadjuvant (Z)-endoxifen for pre-menopausal women with ER+/HER2- breast cancer was authorized by FDA to begin in the United States, and we plan to initiate the study during the fourth quarter of this year. We are re-aligning our strategy to address new avenues in the field of oncology. We have altered our approach to the development of AT-H201 in cancer patients with compromised lung-function resulting from cancer treatment, and are beginning to explore the possibility of pursuing immune-oncology programs. In the meantime, we will continue our current programs and will provide progress updates as they become available,” commented Dr. Steven Quay, Atossa’s President and Chief Executive Officer.

Quarter Ended September 30, 2022 Financial Results (in thousands):

As of September 30, 2022, the Company had cash, cash equivalents and restricted cash of approximately $117,477.

Revenue and Cost of Revenue: For the three months ended September 30, 2022 and 2021, we had no source of revenue and no associated cost of revenue.

Operating Expenses: Total operating expenses were $8,205 for the three months ended September 30, 2022, which is an increase of $3,047 or 59% from operating expenses for the three months ended September 30, 2021 of $5,158. Operating expenses for the three months ended September 30, 2022 consisted of research and development (R&D) expenses of $5,160 and general and administrative (G&A) expenses of $3,045. Operating expenses for the three months ended September 30, 2021 consisted of R&D expenses of $2,206, and G&A expenses of $2,952. The basis for factors contributing to the increased operating expenses in the three months ended September 30, 2022 are explained below.

Research and Development Expenses: R&D expenses for the three months ended September 30, 2022 were $5,160, an increase of $2,954 or 134% from total R&D expenses for the same period in 2021 of $2,206. The increase in R&D expenses was primarily driven by increases in clinical and non-clinical trial costs as well as drug formulation and analysis costs of $2,475. Stock-based compensation expense also increased $62 compared to the prior year period, and other R&D compensation expense increased $85 due to salary, bonus, and benefit increases.

General and Administrative Expenses: G&A expenses were $3,045 for the three months ended September 30, 2022, an increase of $93 or 3% from the total G&A expenses of $2,952 for the three months ended September 30, 2021. The increase in G&A expenses was primarily driven by an increase in legal fees, professional fees and other expenses of $159 for the three months ended September 30, 2022. G&A expenses also increased in part due to an increase in salary, bonus, and benefits of $123, which was offset by a decrease in stock-based compensation expense of $190.

Nine Months Ended September 30, 2022 Financial Results (in thousands):

Revenue and Cost of Revenue: For the nine months ended September 30, 2022 and 2021, we had no source of revenue and no associated cost of revenue.

Operating Expenses: Total operating expenses were $19,553 for the nine months ended September 30, 2022, which is an increase of $3,860 or 25% from operating expenses for the nine months ended September 30, 2021 of $15,693. Operating expenses for the nine months ended September 30, 2022 consisted of R&D expenses of $10,097 and G&A expenses of $9,456. Operating expenses for the nine months ended September 30, 2021 consisted of R&D expenses of $7,383 and G&A expenses of $8,310. The basis for factors contributing to the increased operating expenses in the nine months ended September 30, 2022 are explained below.

Research and Development Expenses: R&D expenses for the nine months ended September 30, 2022 were $10,097, an increase of $2,714 or 37% from total R&D expenses for the same period in 2021 of $7,383. R&D expenses increased due to an increase in spending on clinical and non-clinical trials of $2,910. Compared to the prior year period, stock-based compensation expense also increased $763, and other R&D compensation expense increased $288 due to salary, bonus, and benefit increases in the nine months ended September 30, 2022. Professional expenses also increased $430 during the nine months ended September 30, 2022, as compared to the same period in 2021. The increases in R&D expenses were offset in part by a refund of $1,000 from the research institution with which the Company had an exclusive right to negotiate for the acquisition of the world-wide rights to two oncology R&D programs in February 2022. In the nine months ended September 30, 2021, R&D expenses included $1,000 attributable the same one-time fee, which was paid in June 2021. Finally, on June 27, 2022, we paid $300 for the exclusive right to negotiate with a CAR-T Company.

General and Administrative Expenses: G&A expenses were $9,456 for the nine months ended September 30, 2022, an increase of $1,146 or 14% from the total G&A expenses for the nine months ended September 30, 2021 of $8,310. The increase in G&A expenses for the nine months ended September 30, 2022 was primarily due to the increase in stock-based compensation expense of $832. Compensation expense also increased $554 due to salary, bonus, and benefit increases related to the addition of employees in the nine months ended September 30, 2022. Legal fees also increased $321 compared to the prior year period due to increased patent prosecution activity. These increases are offset in part by a decrease in professional fees and other expenses of $562 due primarily to the reduction of proxy solicitation costs compared to the prior year period.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. For more information, please visit www.atossatherapeutics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201 and (Z)-endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in breast density, Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for (Z)-endoxifen, whether Atossa can complete acquisitions, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:
Atossa Therapeutics, Inc.
Kyle Guse CFO and General Counsel
Office: (866) 893-4927
kyle.guse@atossainc.com

Investor Relations Contact:
Core IR
Office: (516) 222-2560
ir@atossainc.com

Source: Atossa Therapeutics, Inc.

ATOSSA THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except for par value)

As of September 30,
2022 As of December 31,
(Unaudited) 2021
Assets
Current assets
Cash and cash equivalents $ 117,367 $ 136,377
Restricted cash 110 110
Prepaid expenses 5,107 2,488
Research and development rebate receivable 610 1,072
Other current assets 201 1,193
Total current assets 123,395 141,240
Deposit on investment in equity securities 2,700
Other assets 629 22
Total Assets $ 126,724 $ 141,262
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable $ 1,653 $ 1,717
Accrued expenses 117 204
Payroll liabilities 1,071 1,184
Other current liabilities 27 21
Total current liabilities 2,868 3,126
Total Liabilities 2,868 3,126
Commitments and contingencies
Stockholders’ equity
Series B convertible preferred stock – $0.001 par value; 10,000 shares authorized; 1 share issued and outstanding as of September 30, 2022 and December 31, 2021
Additional paid-in capital – Series B convertible preferred stock 582 582
Common stock – $0.18 par value; 175,000 shares authorized; 126,624 shares issued and outstanding as of September 30, 2022 and December 31, 2021 22,792 22,792
Additional paid-in capital – common stock 249,239 243,996
Accumulated deficit (148,703 ) (129,234 )
Accumulated other comprehensive loss (54 )
Total Stockholders’ Equity 123,856 138,136
Total Liabilities and Stockholders’ Equity $ 126,724 $ 141,262


ATOSSA THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(amounts in thousands, except for per share amounts)

For the Three Months Ended September 30, For the Nine Months Ended September 30,
2022 2021 2022 2021
Operating expenses
Research and development $ 5,160 $ 2,206 $ 10,097 $ 7,383
General and administrative 3,045 2,952 9,456 8,310
Total operating expenses 8,205 5,158 19,553 15,693
Operating loss (8,205 ) (5,158 ) (19,553 ) (15,693 )
Other income (expense), net 194 (39 ) 84 (81 )
Loss before income taxes (8,011 ) (5,197 ) (19,469 ) (15,774 )
Income taxes
Net loss (8,011 ) (5,197 ) (19,469 ) (15,774 )
Foreign currency translation adjustment (54 ) (54 )
Comprehensive loss $ (8,065 ) $ (5,197 ) $ (19,523 ) $ (15,774 )
Loss per share of common stock – basic and diluted $ (0.06 ) $ (0.04 ) $ (0.15 ) $ (0.14 )
Weighted average shares outstanding – basic and diluted 126,624 126,538 126,624 113,690


Primary Logo

Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy

Regulatory Approval To Open Clinical Study of AT-H201 in Australia

SEATTLE, Nov. 01, 2022 — Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (DCT). Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments.

“This investment in DCT is an important step in pursuing our strategy to develop CAR-T therapies or adjacent opportunities within the immuno-oncology space,” commented Steven Quay, M.D., Ph.D., Atossa’s CEO, Chairman and President. “We believe that as an active investor in the development of DCT we will be well positioned to evaluate future opportunities while strategically managing our cash position.”

Atossa will acquire shares equal to 19.99% of the outstanding capital stock of DCT as of today for a cash payment of $2 million (in addition to $3 million previously paid to DCT). The transaction is expected to close in the fourth quarter.

About Dynamic Cell Therapies

Dynamic Cell Therapies is venture capital backed and based in Boston, MA. DCT is in the pre-clinical phase of developing controllable CAR-T cells to address difficult-to-treat cancers. Its platform technology of dynamic control of engineered T-cells is designed to improve the safety, efficacy, and durability of CAR-T cell therapies. This system should find initial applications in hematological cancers, with future approaches in solid tumors and autoimmune diseases. The company’s platform technology uncouples tumor targeting from CAR-T cell activation. Each CAR-T cell recognizes an inert small molecule. This small molecule is conjugated to a tumor-specific antibody. By dosing a small molecule-antibody conjugate, the physician could dynamically control CAR-T cell activity and potentially minimize the risk of life-threatening side effects. Increasing the dose of the small molecule-antibody conjugate should strengthen the immune attack against tumor cells. In addition, the same small molecule can be coupled to different tumor targeting antibodies, allowing the physician to maximize on-target on-tumor efficacy and reduce off-tumor toxicities. To learn more, please visit www.dynamiccelltherapies.com.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments.

For more information, please visit www.atossatherapeutics.com

Contact:

Atossa Therapeutics, Inc.
Kyle Guse, General Counsel and Chief Financial Officer
kyle.guse@atossainc.com


Primary Logo

Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.

Regulatory Approval To Open Clinical Study of AT-H201 in Australia
Oversaw FDA approval of CAR-T/CAR-NK cell therapy, ADCs, and small molecule/targeted therapies for hematology-oncology diseases

SEATTLE, Oct. 25, 2022 — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and adjunctive treatments for cancer radiotherapy, announces today that it has retained Richard Graydon, M.D., Ph.D. as interim chief medical officer. Dr. Graydon will devote all of his professional time to the Atossa clinical programs.

Prior to joining Atossa, Dr. Graydon served as Senior Director of Clinical Development at Johnson and Johnson where he was responsible for leading compound development and clinical trial programs for Janssen Pharmaceuticals. At Janssen, he oversaw the early to late-stage development and the 2022 approval of BCMA-directed CAR T-Cell therapy (cilta-cel) for Multiple Myeloma, as well as daratumumab, imbruvica, siltuximab and other compounds for solid tumor and hematological malignancies. Previously, he held the role of Director of Clinical Development at Daiichi Sankyo, Inc., where he led the early and late-stage development of the small molecule targeted therapy quizartinib for FLT3-positive Acute Myeloid Leukemia. Additionally, he led the early-stage development of the MDM2 inhibitor milademetan in hematological malignancies and liposarcomas. Dr. Graydon spent time in clinical practice following completion of his specialty training in hematology and oncology at Harvard Massachusetts General Hospital. He earned his M.D. and Ph.D. at Stanford University, and undergraduate degree in Chemical Engineering at Cornell University. Dr. Graydon is the author of The Genetic Risks of Cancer: The Effects of DNA, Genomics and Inheritance on Aging and Survival.

“We are privileged to welcome Richard to Atossa, where his deep experience in CAR T cell therapy fits well with our current strategic direction as we explore our opportunities in cell therapy,” said Steven Quay, M.D., Ph.D., Atossa’s Chairman, CEO and President. “We look forward to collaborating with Richard to assess our strongest options and develop a pathway that provides our shareholders with strong results and enhanced shareholder value.”

“I’m looking forward to collaborating with Atossa’s management team and board of directors as we continue to develop the Company’s Phase 2 oral Endoxifen program for breast cancer and identify new opportunities for Atossa in cell therapy,” added Dr. Graydon.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and adjunctive treatments for cancer radiotherapy.

For more information, please visit www.atossatherapeutics.com

Contact:

Atossa Therapeutics, Inc.
Kyle Guse, General Counsel and Chief Financial Officer
kyle.guse@atossainc.com


Primary Logo

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

Regulatory Approval To Open Clinical Study of AT-H201 in Australia
Atossa to begin Phase 2 Study of (Z)-endoxifen in 4th Quarter

SEATTLE, Oct. 24, 2022 — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer, announced today that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and authorized initiation of its Phase 2 neoadjuvant clinical study of (Z)-endoxifen in premenopausal women with early-stage estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer. This is the first study of Atossa’s proprietary (Z)-endoxifen in the United States.

At this time, Atossa also announced that it is discontinuing its COVID-19 program (AT-301) so that it can refocus resources on this critical study in breast cancer.

“Continuing the development of our proprietary (Z)-endoxifen here in the United States has been a key goal which builds on the recent issuance of a U.S. patent for our proprietary (Z)-endoxifen and results from our Phase 2 “window-of-opportunity” study in Australia,” commented Steven Quay, M.D., Ph.D., Atossa’s CEO, Chairman and President. “We are excited to have engaged Dr. Matthew Goetz, the Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D. at Mayo Clinic and Director of the Mayo Clinic Breast Cancer SPORE, as the lead principal investigator for this multi-center study. We look forward to opening the study in the fourth quarter.”

About the Study

The study, “A Randomized Phase 2 Noninferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment in Premenopausal Women with ER+/HER2- Breast Cancer”, or also known as “EVANGELINE,” is an open-label, randomized, Phase 2 study designed to investigate (Z)-endoxifen for the neoadjuvant treatment of premenopausal women ages 18 and older with early stage (Grade 1 or 2) ER+/HER2- breast cancer. InClin Inc., a full-service Contract Research Organization, has been contracted to execute this study.

This study is a multicenter (approximately 25 sites) study in United States and will enroll about 175 patients and is designed with two cohorts: a PK Run-In Cohort to investigate pharmacokinetics and identify a dose for the Treatment Cohort and a Treatment Cohort to investigate the safety and efficacy of (Z)-endoxifen compared with a prospective control (exemestane + goserelin, two drugs often used in combination to treat this patient population).

The primary objective of the study is to assess whether the endocrine sensitive disease rate at 4 weeks with (Z)-endoxifen is non-inferior to exemestane plus goserelin in premenopausal women with ER+/HER2- breast cancer. Endocrine sensitivity, or the effect of endocrine therapy on the tumor, will be measured by Ki-67%, a biomarker for tumor cell proliferation. Ki-67 is known to be prognostic for 5-year disease-free survival in the neoadjuvant endocrine treatment of ER+/HER2- breast cancer. The neoadjuvant setting of this study will allow Atossa to investigate several translational endpoints using paired tumor samples.

Patients will be enrolled with the intent of surgical treatment in the involved breast(s) after completing neoadjuvant study treatment. Patients will receive neoadjuvant study treatment for up to six months. Surgery will be performed within seven days of the last dose of study treatment.

About Premenopausal Patients with ER+/HER2- Breast Cancer

Breast cancer is the most frequently diagnosed cancer in premenopausal women worldwide. It is estimated that almost half of the cancers that occur in women aged 15-49 is breast cancer. An overwhelming majority (75%) of premenopausal breast cancer falls under luminal A (ER+/HER2-) or B (ER+/HER2+) subtypes. Ovarian function suppression, when combined with either tamoxifen or an aromatase inhibitor, is the standard of care for the endocrine management of premenopausal ER+/HER2- breast cancer.

About (Z)-Endoxifen

(Z)-endoxifen is the most active metabolite of the FDA approved Selective Estrogen Receptor Modulator (SERM), tamoxifen. Studies by others have demonstrated that the anti-estrogenic effects of tamoxifen are driven in a concentration-dependent manner by (Z)-endoxifen. In addition to its anti-estrogen effects, (Z)-endoxifen at higher concentrations has been shown to target PKCβ1, a known oncogenic protein.

Atossa has developed a proprietary oral formulation of (Z)-endoxifen that does not require liver metabolism to achieve therapeutic concentrations and is encapsulated to bypass the stomach as acidic conditions may render (Z)-endoxifen inactive. Atossa’s (Z)-endoxifen has been shown to be well tolerated in Phase 1 studies and in a small Phase 2 study of women with breast cancer. We currently are studying our (Z)-endoxifen in healthy women with measurable breast density and premenopausal women with ER+/HER2- breast cancer.

Atossa has been issued U.S. Patent No. 11,261,151, titled “Methods for Making and Using Endoxifen” which is directed to compositions of storage-stable (Z)-endoxifen and methods of treating hormone-dependent breast disorders using the storage-stable (Z)-endoxifen. This patent is not expected to expire until 2038.

Update on Ongoing Phase 2 Study of (Z)-Endoxifen Phase 2 Study in Stockholm

The Company has continued to make steady progress with its ongoing study of (Z)-endoxifen in premenopausal women with measurable breast density in Stockholm, Sweden. It has now enrolled approximately 40% of the subjects in that study, which puts Atossa on track to completing enrollment of all 240 participants in the second half of 2023.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer.

For more information, please visit www.atossatherapeutics.com.

Forward Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201 and (Z)-endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in breast density or in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for (Z)-endoxifen, whether Atossa can complete acquisitions, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Contact:
Atossa Therapeutics, Inc.
Kyle Guse, General Counsel and Chief Financial Officer
kyle.guse@atossainc.com


Primary Logo

Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference

Regulatory Approval To Open Clinical Study of AT-H201 in Australia

Atossa logo

 View All
Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announced today that Kyle Guse, General Counsel & Chief Financial Officer will attend the 24th Annual H.C. Wainwright Global Investment Conference being held on September 12 – 14, 2022 at the Lotte New York Palace.

Mr. Guse will be available for one-on-one meetings. To request a meeting and to register for the conference, click below:

https://hcwevents.com/annualconference/

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

For more information, please visit www.atossatherapeutics.com

Contact:

Atossa Therapeutics, Inc.
Kyle Guse, General Counsel and Chief Financial Officer
kyle.guse@atossainc.com


Primary Logo

Sep 07, 2022

Registration Now Open for Tribe Public’s Webinar Event “The Important Role For Inhalation Therapy In Oncology” Featuring The Management Team From Atossa Therapeutics on August 25, 2022

Regulatory Approval To Open Clinical Study of AT-H201 in Australia

Atossa logo

 View All
Registration Now Open for Tribe Public’s Webinar Event “The Important Role For Inhalation Therapy In Oncology” Featuring The Management Team From Atossa Therapeutics on August 25, 2022
Meet with Atossa’s CEO & Founder, Dr. Steven Quay, M.D., Ph.D. & Kyle Guse, GC & CFO

SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announces that Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., and Kyle Guse, GC & CFO will present at Tribe Public’s Webinar Presentation and Q&A Event that is scheduled to begin at 8am pacific/11am eastern on Thursday, August 25th. During this complimentary event, Atossa management will speak new opportunities for its inhalation therapy, AT-H201, to potentially treat lung injury caused by cancer treatment and will be available for a Q&A session focused on Atossa’s research programs and future development. To join the complimentary event, please register at ATOSAUG25.TribePublic.com. Once registered, Tribe members may then send their questions for Atossa’s management to research@tribepublic.com. Tribe Public’s Managing Member, John F. Heerdink, Jr., will host the event.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

About Tribe Public LLC

Tribe Public LLC is a San Francisco, CA-based organization that hosts complimentary worldwide webinar & meeting events in the U.S. Tribe’s events focus on issues that the Tribe’s members care about with an emphasis on hosting management teams and experts from publicly traded companies from all sectors & financial organizations that are seeking to increase awareness of their products, progress, and plans. Tribe members primarily include Institutions, Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and members of media. Tribe Members are encouraged to express their interest in speakers at the Tribe Public website via the Tribe’s FREE “Wish List” process. Visit Tribe Public’s Website http://www.tribepublic.com/ to join the Tribe and express your interests today.

COMPANY CONTACT:
Atossa Therapeutics, Inc.
Kyle Guse, General Counsel and Chief Financial Officer
kyle.guse@atossainc.com


Primary Logo

Aug 22, 2022

Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board

Regulatory Approval To Open Clinical Study of AT-H201 in Australia

Atossa logo

 View All
Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board
The Company Re-Appoints Drs. Mak Jawadekar, Per Hall, and Carl Novina

SEATTLE, Aug. 18, 2022 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces the appointment of Dr. Paul Wabnitz to its Scientific Advisory Board (SAB). The Company has also re-appointed Drs. Mak Jawadekar, Per Hall, and Carl Novina to the SAB.

“We are delighted to welcome Dr. Wabnitz to our SAB, as he has been instrumental in our activities to reposition our inhalation therapy, AT-H201, to potentially treat lung injury caused by cancer treatment,” stated Steven Quay, M.D., Ph.D., Atossa’s CEO, Chairman and President. “Further, we are pleased to welcome back Drs. Jawadekar, Hall and Novina, each of whom has played a valuable role in Atossa’s product development. We continue to rely on their counsel as we advance our programs through the clinic.”

Dr. Wabnitz has extensive experience in clinical development with a unique combination of clinical medicine, pharmacology, toxicology, and industry drug development experience. He has acted as an investigator and Medical Monitor on over 50 first in human Phase I/II clinical trials over the last two years, including several Phase I/II first in human oncology studies, as well as previously being the Executive Medical Director of a leading Australian Phase I clinical unit. His scientific background includes a Ph.D. in Organic Chemistry, a Post Doc at Parke-Davis (Ann Arbor, MI), 6.5 years of drug development industry experience (Pfizer/Esperion), an M.B.A. from the Stephen Ross School of Business (University of Ann Arbor, MI), and a Drug Development certificate in Regulatory Affairs from Temple University (Philadelphia, PA). His clinical background includes a Doctor of Medicine (M.D.), and he is a qualified Specialist Physician and Clinical Pharmacologist (Fellow of the Royal Australasian College of Physician, Australia).

Dr. Hall is a professor of epidemiology and widely regarded as a leading researcher in the field of breast cancer prevention, early detection and risk modelling. He was previously Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. Dr. Hall is leading the unique KARMA (Karolinska Mammography Project for Risk Prediction of Breast Cancer) Cohort (www.karmastudy.org), including over 70,000 women, which is regarded as the best characterized breast cancer cohort in the world and serves as a resource for studies about breast cancer risk assessment and prevention. He also headed several breast cancer prevention trials where mammographic breast density change is used as a proxy for therapy response. Dr. Hall is the Principal Investigator on Atossa’s ongoing Phase 2 study of Endoxifen in women with breast density.

Dr. Novina is a thought leader in the biology of non-coding RNAs and their dysregulation in cancers. His lab has also built biomedical tools, which are being developed for cancer immunotherapy. He is currently an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT.

Dr. Mak Jawadekar is currently an independent Pharma Professional. He worked at Pfizer, Inc. based in Groton-New London Connecticut for 28 consecutive years mostly in the R & D Division. In 2010, he served as a Director, Portfolio Management at Pfizer Inc. During his career at Pfizer, he was responsible for Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies. He has extensive experience in creating and cultivating external partnerships and alliances for Drug Delivery Technologies. While working on “Pfizer’s EXUBERA” (Inhaled Insulin) development, he closely collaborated with Inhale Therapeutics Inc. which is now known as EKTAR Therapeutics. He also worked with Boehringer-Ingelheim- Pfizer collaboration on SPIRIVA, an inhalation formulation/device combo therapy development for COPD. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics, under Prof. Ed Rippie at the University of Minnesota.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

For more information, please visit www.atossatherapeutics.com

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risk and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence and continue studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from neoadjuvant study or reduction of breast density will be approvable endpoints for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:

Atossa Therapeutics, Inc.
Kyle Guse, General Counsel and Chief Financial Officer
kyle.guse@atossainc.com


Primary Logo

Aug 18, 2022

Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Regulatory Approval To Open Clinical Study of AT-H201 in Australia

Atossa logo

 View All
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments.

Key developments from Q2 2022 and to date include:

  • Completed dosing in both Part B and Part C (of four parts) of Phase 1/2a Clinical Trial of AT-H201 in healthy volunteers, which the Company was developing as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease.
  • Announced plans to shift the development of AT-H201 to more closely align with its oncology focus by continuing the development in patients with compromised lung function due to the damaging effects of cancer treatment.
  • Entered into an agreement with a venture-capital backed, private company based in the United States that is in the pre-clinical stage of developing novel Chimeric Antigen Receptor (CAR) T-cell therapies based on technology licensed from a leading U.S. adult and pediatric cancer treatment and research institution. The agreement requires that up until November 1, 2022 the CAR-T company will negotiate exclusively with Atossa for Atossa to acquire the CAR-T company, and address certain matters related to personnel, operations and intellectual property.
  • Filed an investigational new drug application with the FDA to initiate a Phase 2 neoadjuvant clinical study of Atossa’s proprietary Endoxifen in premenopausal women with early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancer in the United States. The FDA has issued a clinical hold letter requesting additional information which Atossa plans to submit by the end of the third quarter 2022 and to initiate enrollment in the fourth quarter 2022.

“We continue to make steady progress with our Endoxifen programs: one to reduce tumor cell activity in breast cancer patients in the neoadjuvant setting; and another to reduce dense breast tissue in women. Our work on AT-H201 demonstrated valuable outcomes, not the least of which was an understanding of how to pursue its development in the field of oncology. With the widespread availability of SARS-CoV-2 vaccines and other therapies now approved to treat COVID-19, we believe that altering the development pathways for AT-H201 in cancer patients with compromised lung-function resulting from radiation treatment may fill a compelling unmet medical need and create additional value for our stockholders. Lung injury caused by radiation treatment affects 30-40% of lung cancer patients, and ~35% of esophageal cancer patients. In non-small cell cancer patients receiving concurrent chemotherapy and radiation therapy the incidence of lung injury is estimated to be greater than 60%. As we previously announced, rather than proceeding with Part D of the AT-H201 study in COVID-19 patients, we plan to quickly initiate a clinical study of patients with compromised lung function caused by radiation treatment and we anticipate announcing next steps in the coming months,” commented Dr. Steven Quay, Atossa’s President and Chief Executive Officer.

Quarter Ended June 30, 2022 Financial Results (in thousands):

As of June 30, 2022, the Company had cash, cash equivalents and restricted cash of approximately $125,647.

For the quarter ended June 30, 2022, Atossa had no source of sustainable revenue and no associated cost of revenue.

Operating Expenses: Total operating expenses were $6,595 for the three months ended June 30, 2022, which is a decrease of $409 or 6%, from the three months ended June 30, 2021, of $7,004. Operating expenses for 2022 consisted of research and development (R&D) expenses of $3,433 and general and administrative (G&A) expenses of $3,162. Operating expenses for 2021 consisted of R&D expenses of $3,799, and G&A expenses of $3,205.

Research and Development Expenses: R&D expenses for the three months ended June 30, 2022, were $3,433, a decrease of $366 or 10% from total R&D expenses for the same period in 2021 of $3,799. Clinical and non-clinical trial costs as well as drug formulation and analysis for our clinical trials were consistent quarter over quarter. Total R&D compensation expense increased primarily due to an increase in stock-based compensation of $270 and increased salaries, bonus and benefits of $123. In addition, the Company paid a no-shop fee of $300 to negotiate the potential acquisition of a company focused on the pre-clinical stage of developing novel Chimeric Antigen Receptor (CAR) T-cell therapies based on technology licensed from a leading U.S. cancer treatment and research institution. Included in 2021 R&D expenses is an increase of $1,000 attributable to a one-time fee we paid in June 2021 to a U.S. leading research institution for the exclusive right to negotiate for the acquisition of the world-wide rights to two oncology R&D programs.

General and Administrative Expenses: G&A expenses were $3,162 for the three months ended June 30, 2022, a decrease of $43, or 1% from the total G&A expenses for the three months ended June 30, 2021, of $3,205. G&A expenses for the three months ended June 30, 2022, increased $454 primarily due to an increase in non-cash stock-based compensation expense of $287 and an increase in other compensation of $167 due to the addition of a new employee quarter over quarter as well as salary, bonus and benefits increases. This increase was offset by a decrease of $533 in professional fees primarily due to a decrease in proxy costs in 2022.

Six Months Ended June 30, 2022 Financial Results (in thousands):

For the six months ended June 30, 2022, Atossa had no source of sustainable revenue and no associated cost of revenue.

Operating Expenses: Total operating expenses were $11,348 for the six months ended June 30, 2022, which is an increase of $814 or 8%, from the six months ended June 30, 2021 of $10,534. Operating expenses for 2022 consisted of R&D expenses of $4,937 and general and G&A expenses of $6,411. Operating expenses for 2021 consisted of R&D expenses of $5,177, and G&A expenses of $5,357.

Research and Development Expenses: R&D expenses for the six months ended June 30, 2022, were $4,937, a decrease of $240 or 5% from total R&D expenses for the same period in 2021 of $5,177. R&D expenses decreased because of a refund of $1,000 from the research institution that the Company had an exclusive right to negotiate for the acquisition of the world-wide rights to two oncology R&D programs. In February 2022, the other party did not honor its obligation to negotiate with us which lead to a cancellation of the agreement and refund of the $1,000 previously paid. Included in 2021 R&D expenses is an increase of $1,000 attributable the same one-time fee paid in June 2021. Additionally, on June 27, 2022, this decrease was offset by increased spending on clinical and non-clinical trials of $434 over the same period in 2021 due to additional drug manufacturing costs. Stock-based compensation, which is a non-cash charge, also increased $703 period over period, and other R&D compensation was up $202 due to salary, bonus and benefit increases. Professional expenses also increased $100 during the six months ended June 30, 2022 as compared to the same period in 2021. Finally, we paid $300 for the exclusive right to negotiate with a CAR-T Company for us to acquire the company.

General and Administrative Expenses: G&A expenses were $6,411 for the six months ended June 30, 2022, an increase of $1,054 or 20% from the total G&A expenses for the six months ended June 30, 2021, of $5,357. The increase in G&A expenses for the six months ended June 30, 2022, is primarily attributable to the increase in non-cash stock-based compensation expense of $1,020. Compensation expense also increased $431 due to the addition of a two new employees year over year as well as salary, bonus and benefit increases. Legal fees also increased $147 period over period due to increased patent activity. These increases are offset by the decrease in professional fees of $532 due primarily to the reduction of proxy costs period over period.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious diseases with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, whether Atossa can complete acquisitions, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:
Atossa Therapeutics, Inc.
Kyle Guse CFO and General Counsel
Office: (866) 893-4927
kyle.guse@atossainc.com

Investor Relations Contact:
Core IR
Office: (516) 222-2560
ir@atossainc.com

Source: Atossa Therapeutics, Inc.

ATOSSA THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except for par value)

As of June 30,
2022 As of December 31,
Assets (Unaudited) 2021
Current assets
Cash and cash equivalents $ 125,537 $ 136,377
Restricted cash 110 110
Prepaid expenses 5,304 2,488
Research and development rebate receivable 900 1,072
Other current assets 1,570 1,193
Total current assets 133,421 141,240
Other assets 627 22
Total Assets $ 134,048 $ 141,262
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable $ 2,052 $ 1,717
Accrued expenses 834 204
Payroll liabilities 875 1,184
Other current liabilities 31 21
Total current liabilities 3,792 3,126
Total Liabilities 3,792 3,126
Commitments and contingencies
Stockholders’ equity
Preferred stock – $0.001 par value; 10,000 shares authorized; 1 share issued and outstanding as of June 30, 2022 and December 31, 2021
Additional paid-in capital – Series B convertible preferred stock 582 582
Common stock – $0.18 par value; 175,000 shares authorized; 126,624 shares issued and outstanding as of June 30, 2022 and December 31, 2021 22,792 22,792
Additional paid-in capital – common stock 247,573 243,996
Accumulated deficit (140,691 ) (129,234 )
Total Stockholders’ Equity 130,256 138,136
Total Liabilities and Stockholders’ Equity $ 134,048 $ 141,262

ATOSSA THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(amounts in thousands, except for per share amounts)

For the Three Months Ended June 30, For the Six Months Ended June 30,
2022 2021 2022 2021
Operating expenses
Research and development $ 3,433 $ 3,799 $ 4,937 $ 5,177
General and administrative 3,162 3,205 6,411 5,357
Total operating expenses 6,595 7,004 11,348 10,534
Operating loss (6,595 ) (7,004 ) (11,348 ) (10,534 )
Other expense, net (77 ) (35 ) (109 ) (43 )
Loss before income taxes (6,672 ) (7,039 ) (11,457 ) (10,577 )
Income taxes
Net loss $ (6,672 ) $ (7,039 ) $ (11,457 ) $ (10,577 )
Loss per common share – basic and diluted $ (0.05 ) $ (0.06 ) $ (0.09 ) $ (0.10 )
Weighted average shares outstanding – basic and diluted 126,624 121,572 126,624 107,160


Primary Logo

Aug 08, 2022

Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

Regulatory Approval To Open Clinical Study of AT-H201 in Australia

Atossa logo

 View All
Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers
Atossa Plans to Initiate a New Development Path in Patients with Compromised Lung-Function Resulting from Cancer Treatment

SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces it has completed dosing participants in Part C of its Phase 1/2a clinical study of its proprietary inhalation therapy (or, AT-H201) in Australia.

AT-H201 consists of two drugs previously approved by the FDA to treat other diseases. AT-H201 is intended to be inhaled via nebulizer with the goal of preventing or reducing lung injury that may be caused by fibrin deposition, fluid build-up and secondary infection.

Part C of the study involved administering the two drugs in succession in healthy volunteers. The study originally included a Part D which was designed to assess the effects of the treatment regimen in hospitalized COVID-19 patients with moderate illness. However, due to the rapidly shifting COVID-19 treatment landscape and the introduction of effective vaccines limiting hospitalizations, Atossa has evaluated indications for AT-H201 beyond COVID-19 patients, including treating and/or preventing lung injury in patients undergoing certain cancer treatments.

Rather than conducting Part D of the Phase 1/2a clinical study, Atossa now plans to shift the development of AT-H201 to closely align with its oncology focus by continuing the development in patients with compromised lung-function due to the damaging effects of cancer treatment. For example, radiation treatment can lead to radiation induced lung injury, which is poorly treated with current therapies and is often irreversible. Furthermore, radiation damage can limit the overall success of lung cancer treatment leading to a reduction in efficacy and poor disease control. AT-H201 has pharmacological properties to potentially curtail excessive radiation-induced lung injury without compromising standard of care cancer therapy for cancer patients. AT-H201 is designed to prevent and reduce dose-limiting toxicities, and enable a more durable therapeutic tumor response for cancer patients receiving pulmonary radiation.

“We are happy to have completed Parts A, B and C of the clinical trial and look forward to evaluating the results,” said Steven Quay, M.D., Ph.D., CEO and President of Atossa. “With widespread availability of SARS-CoV-2 vaccines and other therapies now approved to treat COVID-19, we believe that altering the development pathways for AT-H201 in patients with compromised lung-function resulting from radiation may fill a compelling unmet medical need and create more value for our stockholders.” Based on our work to date with AT-H201, we believe we can quickly initiate a clinical study in this setting and we plan to announce our next steps in the fourth quarter,” concluded Dr. Quay.

Radiation Induced Lung Injury (RILI)

RILI is damage to the lungs caused by ionizing radiation administered to treat cancer. RILI is a significant issue for patients undergoing radiation treatment for various forms of cancer and is often irreversible. For instance, RILI affects 30-40% of lung cancer patients, and ~35% of esophageal cancer patients. In non-small cell cancer patients receiving concurrent chemotherapy and radiation therapy the incidence of RILI is estimated to be greater than 60%. Although Atossa has not finalized the protocol for this new trial we believe RILI affects a significant number of patients across multiple cancer types and there is a meaningful need for new treatments.

About AT-H201

AT-H201 is a proprietary sequential dosing regimen of two previously approved by the FDA to treat other diseases, and by other administration routes. AT-H201 is intended to be inhaled via nebulizer to improve compromised lung function.

The Phase 1/2a study in Australia and other clinical studies must be successfully completed and regulatory approvals must be obtained before AT-H201 can be commercialized. No assurance can be given that the studies will be successful or that regulatory approvals will be obtained.

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

For more information, please visit www.atossatherapeutics.com

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risk and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence and continue studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from neoadjuvant study or reduction of breast density will be approvable endpoints for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:

Atossa Therapeutics, Inc.
Charles Butler
Vice President, Investor and Public Relations
charles.butler@atossainc.com


Primary Logo

Jul 28, 2022

Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

Regulatory Approval To Open Clinical Study of AT-H201 in Australia

Atossa logo

 View All
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces the appointment of Charles Butler, a 25-year veteran in the healthcare communications space, as vice president of investor relations and public relations.

“As Atossa continues to develop our pipeline both in breast cancer and COVID-19, the necessity for an in-house strategic manager for our communications has become an important priority and Charles’s extensive experience within the industry as a liaison for both investors and the media make him a valuable asset,” commented Dr. Steven Quay, Atossa’s President and Chief Executive Officer.

Prior to joining Atossa, Mr. Butler spent 10 years at Exelixis, Inc. where he managed all communications from the preclinical through commercial stage for multiple drugs. During his time at Exelixis, he was a part of the team that raised over $1B in equity and business development transactions. Prior to Exelixis, he worked at Ogilvy in New York and London. At Ogilvy he was part of the team that launched multiple blockbuster drugs for several pharmaceutical companies including Merck and Pfizer. While in London, he managed a 25+ person team, overseeing healthcare communications for the United Kingdom and Europe. He has also worked at Castlight Health, ICR, Adverum, Eiger Biopharmaceuticals and IN8bio, Inc.

Mr. Butler graduated from George Washington University with a B.A. in Political Science.

“The unique opportunity to be part of the Atossa team that is working to bring new products to market in breast cancer and other important diseases is exciting. It will allow me to leverage my many years of experience across the communications spectrum in biotechnology. I look forward to collaborating closely with management to ensure its strong message of innovation and patient care are clearly received in this crowded marketplace,” added Mr. Butler.

ABOUT ATOSSA THERAPEUTICS

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.

FORWARD-LOOKING STATEMENTS DISCLAIMER STATEMENT

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence and continue studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study or reduction of breast density will be approvable endpoints for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

COMPANY CONTACT:

Atossa Therapeutics, Inc.
Kyle Guse, CFO and General Counsel
Office: (866) 893-4927
kyle.guse@atossainc.com

INVESTOR RELATIONS CONTACT:
Core IR
Office: (516) 222-2560
ir@atossainc.com


Primary Logo

Jun 02, 2022